A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts
Portfolio Pulse from Benzinga Insights
Pacira BioSciences (NASDAQ:PCRX) was analyzed by 7 analysts, showing a mix of bullish and somewhat bullish ratings, with no bearish or indifferent stances. The average 12-month price target is $52.71, down from $58.40. Analysts from firms like Raymond James, HC Wainwright & Co., Piper Sandler, RBC Capital, Needham, and Barclays have adjusted their price targets and ratings, reflecting changes in market dynamics and company performance. Pacira BioSciences, known for its non-opioid pain management solutions, has seen a -2.11% revenue decline as of September 30, 2023, but outperforms in net margin and ROE, with a conservative debt-to-equity ratio.
December 20, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pacira BioSciences received mixed analyst ratings with a downward revision in the average price target to $52.71. The company faces revenue challenges but maintains strong profitability metrics.
The mixed analyst ratings and lowered price targets suggest uncertainty, which could lead to a neutral short-term impact on PCRX's stock price. However, the company's strong profitability and financial health metrics may counterbalance the negative revenue trend, maintaining investor confidence.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100